1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028

Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028

  • September 2019
  • 160 pages
  • ID: 5812515
  • Format: PDF
  • By Delve Insight


Table of Contents

‘Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatic Encephalopathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Hepatic Encephalopathy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Hepatic Encephalopathy - Disease Understanding and Treatment Algorithm
The Hepatic Encephalopathy market report gives a thorough understanding of the Hepatic Encephalopathy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatic Encephalopathy in the US, Europe, and Japan.

Hepatic Encephalopathy
The Hepatic Encephalopathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Hepatic Encephalopathy in 7MM, Total Diagnosed Prevalence of Hepatic Encephalopathy in 7MM, Gender-specific Diagnosed Prevalence of Hepatic Encephalopathy, Age-specific Diagnosed Prevalence of Hepatic Encephalopathy, and Type Specific Diagnosed Prevalence of Hepatic Encephalopathy) scenario of Hepatic Encephalopathy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to the analyst, the total number of diagnosed prevalent population of Hepatic Encephalopathy in 7MM was found to be approximately 358,910 in the year 2017.

Hepatic Encephalopathy Drug Chapters
This segment of the Hepatic Encephalopathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Management of overt HE includes treating patients with acute HE episodes, preventing HE recurrence, and identifying and managing precipitating factors associated with the development of HE. The two main forms of medical therapy for HE are non-absorbable disaccharides (i.e., lactitol and lactulose) and non-absorbable antibiotics (i.e. rifaximin). The hyperammonemia and inflammation that occurs due to urea breakdown in cirrhotics have led to the development of HE treatments that target gut bacteria. Treatments for OHE approved by the US Food and Drug Administration (FDA), as well as some unapproved treatments, are available for use. It is important to remember that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance are vital to neurotoxin clearance. Nutrition may also play a key role in managing HE and preventing a recurrence. The second line, less accepted therapies, include probiotics, branched-chain amino acids (BCAAs), flumazenil, zinc, and ammonia scavengers.

The first-line agent used to prevent acute or persistent HE is the nonabsorbable disaccharides (lactulose or lactitol). Clinical trials have established the efficacy of the nonabsorbable disaccharides in enema form to treat acute episodes of HE. Nonabsorbable disaccharides, lactulose, and lactitol (not used in the United States) have long been the mainstay of treatment for HE.

The second-line agents include oral antibiotics (neomycin, metronidazole, and rifaximin) that can reduce urease-producing bacteria in the intestines, resulting in a decrease of ammonia production and absorption through the gastrointestinal tract. The current guidelines recommend the addition of rifaximin to lactulose for the prevention of HE recurrence after the second episode of HE.

The third-line agents available for patients who cannot tolerate the above agents or still have persistent or episodic HE on the above agents are sodium benzoate, zinc, or bromocriptine. In addition, patients with unique situations may also benefit from an agent in this class.

There is only one drug that is going to be launched in 2023 which will contribute to an increase in the market size of Hepatic Encephalopathy. Mallinckrodt Therapeutics is developing MNK-6105/MNK-6106 for treatment and prevention of Hepatic encephalopathy.

Hepatic Encephalopathy Market Outlook
The Hepatic Encephalopathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the analyst, the market of Hepatic Encephalopathy in 7MM was found to be approximately USD 910.0 million in 2017 and is expected to increase from 2017-2028.
Hepatic Encephalopathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatic Encephalopathy Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hepatic Encephalopathy Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Hepatic Encephalopathy Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits 
• This report will help to develop Business Strategies by understanding the trends shaping and driving Hepatic Encephalopathy Infections market 
• Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy market 
• To understand the future market competition in the Hepatic Encephalopathy market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Restless Legs Syndrome - Pipeline Review, H2 2019

Restless Legs Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Restless Legs Syndrome - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2019, provides ...

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019SummaryP2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 16 molecules. The latest report P2X Purinocepto ...

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019’; Glutamate Recepto ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on